PAGANO, L., J. SALMANTON-GARCIA, F. MARCHESI, A. BUSCA, P. CORRADINI, M. HOENIGL, N. KLIMKO, P. KOEHLER, A. PAGLIUCA, F. PASSAMONTI, L. VERGA, B. VISEK, O. ILHAN, G. NADALI, Barbora WEINBERGEROVÁ, R. CORDOBA-MASCUNANO, M. MARCHETTI, G. P. COLLINS, F. FARINA, C. CATTANEO, A. CABIRTA, M. GOMES-SILVA, F. ITRI, J. VAN DOESUM, M. P. LEDOUX, M. CERNAN, O. JAKSIC, R. F. DUARTE, G. MAGLIANO, A. S. OMRANI, N. S. FRACCHIOLLA, A. KULASEKARARAJ, T. VALKOVIC, C. B. POULSEN, M. MACHADO, A. GLENTHOJ, I. STOMA, Zdenek RACIL, K. PIUKOVICS, Milan NAVRATIL, Z. EMARAH, U. SILI, J. MAERTENS, O. BLENNOW, R. BERGANTIM, C. GARCIA-VIDAL, L. PREZIOSO, A. GUIDETTI, M. I. DEL PRINCIPE, M. POPOVA, N. DE JONGE, I. ORMAZABAL-VELEZ, N. FERNANDEZ, I. FALCES-ROMERO, A. CUCCARO, S. MEERS, C. BUQUICCHIO, D. ANTIC, M. AL-KHABORI, R. GARCIA-SANZ, M. M. BIERNAT, M. C. TISI, E. SAL, L. RAHIMLI, N. COLOVIC, M. SCHONLEIN, M. CALBACHO, C. TASCINI, C. MIRANDA-CASTILLO, N. KHANNA, G. A. MENDEZ, V. PETZER, J. NOVAK, C. BESSON, R. DULERY, S. LAMURE, M. NUCCI, G. ZAMBROTTA, Pavel ZAK, G. C. SEVAL, V. BONUOMO, Jiří MAYER, A. LOPEZ-GARCIA, M. V. SACCHI, S. BOOTH, F. CICERI, M. OBERTI, M. SALVINI, M. IZUZQUIZA, R. NUNES-RODRIGUES, E. AMMATUNA, Ales OBR, R. HERBRECHT, L. NUNEZ-MARTIN-BUITRAGO, V. MANCINI, H. SHWAYLIA, M. SCIUME, J. ESSAME, M. NYGAARD, J. BATINIC, Y. GONZAGA, I. REGALADO-ARTAMENDI, L. K. KARLSSON, M. SHAPETSKA, Michaela HANAKOVA, S. EL-ASHWAH, Z. BORBENYI, G. M. COLAK, A. NORDLANDER, G. DRAGONETTI, A. M. E. MARAGLINO, A. RINALDI, C. DE RAMON-SANCHEZ a O. A. CORNELY. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). JOURNAL OF HEMATOLOGY & ONCOLOGY. LONDON: BMC, 2021, roč. 14, č. 1, s. 1-15. ISSN 1756-8722. Dostupné z: https://dx.doi.org/10.1186/s13045-021-01177-0.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
Autoři PAGANO, L. (garant), J. SALMANTON-GARCIA, F. MARCHESI, A. BUSCA, P. CORRADINI, M. HOENIGL, N. KLIMKO, P. KOEHLER, A. PAGLIUCA, F. PASSAMONTI, L. VERGA, B. VISEK, O. ILHAN, G. NADALI, Barbora WEINBERGEROVÁ (203 Česká republika, domácí), R. CORDOBA-MASCUNANO, M. MARCHETTI, G. P. COLLINS, F. FARINA, C. CATTANEO, A. CABIRTA, M. GOMES-SILVA, F. ITRI, J. VAN DOESUM, M. P. LEDOUX, M. CERNAN, O. JAKSIC, R. F. DUARTE, G. MAGLIANO, A. S. OMRANI, N. S. FRACCHIOLLA, A. KULASEKARARAJ, T. VALKOVIC, C. B. POULSEN, M. MACHADO, A. GLENTHOJ, I. STOMA, Zdenek RACIL (203 Česká republika), K. PIUKOVICS, Milan NAVRATIL, Z. EMARAH, U. SILI, J. MAERTENS, O. BLENNOW, R. BERGANTIM, C. GARCIA-VIDAL, L. PREZIOSO, A. GUIDETTI, M. I. DEL PRINCIPE, M. POPOVA, N. DE JONGE, I. ORMAZABAL-VELEZ, N. FERNANDEZ, I. FALCES-ROMERO, A. CUCCARO, S. MEERS, C. BUQUICCHIO, D. ANTIC, M. AL-KHABORI, R. GARCIA-SANZ, M. M. BIERNAT, M. C. TISI, E. SAL, L. RAHIMLI, N. COLOVIC, M. SCHONLEIN, M. CALBACHO, C. TASCINI, C. MIRANDA-CASTILLO, N. KHANNA, G. A. MENDEZ, V. PETZER, J. NOVAK, C. BESSON, R. DULERY, S. LAMURE, M. NUCCI, G. ZAMBROTTA, Pavel ZAK (203 Česká republika), G. C. SEVAL, V. BONUOMO, Jiří MAYER (203 Česká republika, domácí), A. LOPEZ-GARCIA, M. V. SACCHI, S. BOOTH, F. CICERI, M. OBERTI, M. SALVINI, M. IZUZQUIZA, R. NUNES-RODRIGUES, E. AMMATUNA, Ales OBR (203 Česká republika), R. HERBRECHT, L. NUNEZ-MARTIN-BUITRAGO, V. MANCINI, H. SHWAYLIA, M. SCIUME, J. ESSAME, M. NYGAARD, J. BATINIC, Y. GONZAGA, I. REGALADO-ARTAMENDI, L. K. KARLSSON, M. SHAPETSKA, Michaela HANAKOVA (203 Česká republika), S. EL-ASHWAH, Z. BORBENYI, G. M. COLAK, A. NORDLANDER, G. DRAGONETTI, A. M. E. MARAGLINO, A. RINALDI, C. DE RAMON-SANCHEZ a O. A. CORNELY.
Vydání JOURNAL OF HEMATOLOGY & ONCOLOGY, LONDON, BMC, 2021, 1756-8722.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30205 Hematology
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 23.168
Kód RIV RIV/00216224:14110/21:00122744
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1186/s13045-021-01177-0
UT WoS 000707341700001
Klíčová slova anglicky COVID-19; Pandemic; Hematological malignancies; Epidemiology; EHA
Štítky 14110212, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 5. 11. 2021 09:44.
Anotace
Background Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. Methods The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020. Results The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March-May 2020) and the second wave (October-December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value < 0.0001). In the multivariable analysis, age, active malignancy, chronic cardiac disease, liver disease, renal impairment, smoking history, and ICU stay correlated with mortality. Acute myeloid leukemia was a higher mortality risk than lymphoproliferative diseases. Conclusions This survey confirms that COVID-19 patients with HM are at high risk of lethal complications. However, improved COVID-19 prevention has reduced mortality despite an increase in the number of reported cases.
Návaznosti
2015-1-CZ01-KA203-013935, interní kód MUNázev: Medical Curriculum Innovations (Akronym: MEDCIN)
Investor: Evropská unie, Medical Curriculum Innovations, Strategická partnerství v oblasti vzdělávání, odborné přípravy a mládeže
VytisknoutZobrazeno: 18. 7. 2024 15:42